Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US35104E1001
Share Class Description:
FDMT: Ordinary SharesDescription
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 39.69 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.41 | |||||
| Beneish M-Score | 12.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -37 | |||||
| 3-Year EBITDA Growth Rate | 31.7 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year FCF Growth Rate | 37.1 | |||||
| 3-Year Book Growth Rate | -9.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -13.16 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -25.32 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.33 | |||||
| 9-Day RSI | 42.94 | |||||
| 14-Day RSI | 36.13 | |||||
| 6-1 Month Momentum % | -62.21 | |||||
| 12-1 Month Momentum % | -14.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 28.48 | |||||
| Quick Ratio | 28.48 | |||||
| Cash Ratio | 27.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.3 | |||||
| Shareholder Yield % | -79.75 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -649.02 | |||||
| Net Margin % | -543.54 | |||||
| FCF Margin % | -431.13 | |||||
| ROE % | -25.54 | |||||
| ROA % | -23.85 | |||||
| ROIC % | -226.31 | |||||
| 3-Year ROIIC % | -163.08 | |||||
| ROC (Joel Greenblatt) % | -415.17 | |||||
| ROCE % | -29.59 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 17.16 | |||||
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.77 | |||||
| EV-to-EBITDA | 0.81 | |||||
| EV-to-Revenue | -5.03 | |||||
| EV-to-Forward-Revenue | 4.54 | |||||
| EV-to-FCF | 1.19 | |||||
| Price-to-Net-Current-Asset-Value | 0.84 | |||||
| Price-to-Net-Cash | 0.85 | |||||
| Earnings Yield (Greenblatt) % | 129.87 | |||||
| FCF Yield % | -19.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FDMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4D Molecular Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.218 | ||
| EPS (TTM) ($) | -2.3 | ||
| Beta | 3.12 | ||
| Volatility % | 108.75 | ||
| 14-Day RSI | 36.13 | ||
| 14-Day ATR ($) | 0.514049 | ||
| 20-Day SMA ($) | 8.494 | ||
| 12-1 Month Momentum % | -14.05 | ||
| 52-Week Range ($) | 7.9 - 36.25 | ||
| Shares Outstanding (Mil) | 51.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4D Molecular Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4D Molecular Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
4D Molecular Therapeutics Inc Frequently Asked Questions
What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
The current price of FDMT is $8.39. The 52 week high of FDMT is $36.25 and 52 week low is $7.90.
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
The next earnings date of 4D Molecular Therapeutics Inc(FDMT) is 2024-11-08 Est..
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
4D Molecular Therapeutics Inc(FDMT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers